CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Ranibizumab +1 moredrug
Likely dose
Ranibizumab 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01476449
NCT01476449Phase 2Completed
CompareCT.gov

Monthly Ranibizumab Versus Treat and Extend Ranibizumab for Diabetic Macular Edema

Retina Vitreous Associates of Florida·interventional·Posted Nov 22, 2011·Updated May 17, 2019

In Brief

A Phase 2 clinical trial evaluating Ranibizumab for Diabetic Retinopathy and Macular Edema. Completed, enrolled 20 participants across 2 sites.

Detailed Summary

This study is to see whether treating diabetic retinal swelling with ranibizumab injections into the eye monthly is better than treating diabetic retinal swelling with ranibizumab injections into the eye less frequently.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Retinopathy, Macular Edema
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 22, 2011
Enrollment StartNov 1, 2011
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 14.6 years ago

Interventions

Ranibizumabdrug

Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.

Ranibizumabdrug

Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.